段昊

一、基本情况

神经外科副主任医师、硕士研究生导师、临床医学博士。中国抗癌协会肿瘤神经病学专业委员会委员、广东省医学会神经外科分会创新转化医学学组副组长、广东省医学教育协会神经肿瘤专业委员会委员、广东省医学会神经外科分会青年委员、国家神经疾病医学中心脑胶质瘤MDT专科联盟华南联盟理事。获第六届广东医学科技奖一等奖，广州日报“2026实力医生”。主持国家自然科学基金、广东省青年科学基金等，以第一/共同第一作者在《Cancer Cell》、《Nature Communications》、《Genome Medicine》、《中华医学杂志（英文版）》、《中华神经外科杂志》等国内外著名医学期刊发表学术论文20余篇，授权国家发明专利3项、实用新型专利6项，多次在美国及欧洲神经肿瘤会议作学术报告。2016-2018年国家公派至美国常春藤名校宾夕法尼亚大学学习，长期与美国宾夕法尼亚大学、英国剑桥大学、中国香港大学、四川华西医院等国内外知名院校专家保持学术交流合作。出诊时间：星期二下午。

二、教育及工作经历

1. 2024-01 至今，中山大学肿瘤防治中心神经外科，副主任医师

2. 2023-01 至 2023-12，中山大学肿瘤防治中心神经外科，主治医师

3. 2020-07 至 2022-12，中山大学肿瘤防治中心神经外科，住院医师，博士后 

4. 2015-09 至 2020-06, 中山大学, 临床医学博士

5. 2016-11 至 2018-10, 美国宾夕法尼亚大学, 联合培养博士

6. 2012-09 至 2015-06, 中山大学, 临床医学硕士

7. 2007-09 至 2012-06, 哈尔滨医科大学, 临床医学学士

三、学术兼职

中国抗癌协会肿瘤神经病学专业委员会委员

国家神经疾病医学中心脑胶质瘤MDT专科联盟华南联盟理事

广东省医学会神经外科分会创新转化医学学组副组长

广东省医学教育协会神经肿瘤专业委员会委员

广东省医学会神经外科分会青年委员

四、主持科研项目

1. 国家自然科学基金，面上项目，肺癌脑转移中氧化磷酸化抑制与抗PD-1治疗的协同机制研究

2. 国家自然科学基金，青年项目，纤溶酶原对骨髓间充质干细胞促进胶质母细胞瘤进展的调控及机

3. 广东省基础与应用基础研究基金项目，区域联合基金-青年基金项目，DCPS抑制剂RG3039抗胶质母细胞瘤的机制研究

4. 中山大学肿瘤防治中心，易方达“郁金香”优秀人才培养基金，纤溶酶原激活HGF/c-Met通路促进间充质干细胞介导的胶质母细胞瘤进展的研究

五、代表性论著

1. Z. Yang#, S. Wei#, H. Duan#(共一排第三), X. Wang#, D. Zhang#, K. M. Kiang#, Y. Deng#, Y. Yang#, Y. Ku, W. Hu, C. Zou, M. Tang, Y. Jiang, Y. Liu, H. Lan, Z. Chen, G. K. Leung*, W. Jia*, Y. Mou *, L. Liu* and G. Zhang* (2026). "A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities." Nat Commun 17(1). (IF=15.7)

2. D. Xie#, W. F. Tang#, T. Jiang#, H. Duan# (共一排第四), S. Mo, H. Zhang, X. Zhai, Q. Tian, Z. Li, Y. Liang, W. Z. Huang, H. M. Jiang, L. T. On Lee, C. Zhang, W. Zhai, Y. Mou*, W. Z. Zhong* and Z. Hu* (2025). Deciphering genomic evolution of metastatic organotropism with 535 paired primary lung cancers and metastases. Cell Rep 44(10): 116449. (IF=6.9)

3. X. Xing#, J. Zhong#, J. Biermann#, H. Duan# (共一排第四), X. Zhang#, Y. Shi#, Y. Gao, K. He, D. Zhai, F. Luo, Y. Lai, F. Xiao, W. Wang, M. Wang, J. Xu, H. Liu, J. Tang, L. Chu, T. Chen, E. K. D'souza, L. Caprio, L. Ebel, D. Biswas, A. Cottarelli, Y. Mou*, B. Izar*, N. Zhang* and F. Bai* (2025). "Pan-cancer human brain metastases atlas at single-cell resolution." Cancer Cell 43(7): 1242-1260 e1249. (IF=44.5)

4. H. Duan# (共一排第一), J. Ren#, S. Wei#, Z. Yang#, C. Li#, Z. Wang#, M. Li#, Z. Wei*, Y. Liu, X. Wang, H. Lan, Z. Zeng, M. Xie, Y. Xie, S. Wu, W. Hu, C. Guo, X. Zhang, L. Liang, C. Yu, Y. Mou, Y. Jiang, H. Li, E. Sugarman, R. A. Deek, Z. Chen, T. Li, Y. Chen*, M. Yao*, L. Chen*, L. Liu*, G. Zhang* and Y. Mou* (2024). Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target. Genome Med 16(1): 138. (IF=10.4)

5. H. Duan# (共一排第一), Y. Xie#, S. Wu#, G. Zhao#, Z. Zeng, H. Hu, Y. Yu, W. Hu, Y. Yang, Y. Chen, H. Xie, Z. Chen, G. Zhang, K. T. Flaherty, S. Hu, H. Xu*, W. Ma* and Y. Mou* (2024). Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma. J Transl Med 22(1): 880. (IF=6.1)

6. H. Duan# (共一排第一), Z. He#, Z. Chen#, Y. Chen#, W. Hu, K. Sai, X. Zhang, J. Xia, Y. Li, R. Liu, C. Zou, Z. Chen and Y. Mou* (2024). Long-term survival after local immunotherapy for malignant gliomas: a retrospective study with 20 years follow-up. BMC Immunol 25(1): 83.  (IF=2.9)

7. R. Cui#, H. Duan# (共一排第二), W. Hu#, C. Li, S. Zhong, L. Liang, S. Chen, H. Hu, Z. He, Z. Wang, X. Guo, Z. Chen, C. Xu, Y. Zhu, Y. Chen, K. Sai, Q. Yang, C. Guo*, Y. Mou* and X. Jiang* (2024). Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening. J Clin Endocrinol Metab. (IF=5.0)

8. Y. Zou#, H. Duan# (共一排第二), Z. Deng#, R. Xiang#, J. Zhao, Z. Zhang, W. Hu, Y. Yang, Z. Yan, S. Wen, Z. Liu, G. Zhang*, Y. Mou*, D. Li* and X. Jiang* (2024). Single-cell atlas profiling revealed cellular characteristics and dynamic changes after PD-1 blockade therapy of brain metastases from laryngeal squamous cell carcinoma. Mol Cell Biochem. (IF=3.5)

9. Lanyang Xu#, Hao Duan# (共一排第二), Yuheng Zou#, Jing Wang, Huaxi Liu, Wanyu Wang, Xiao Zhu, Jiali Chen, Chuanwu Zhu, Zhixin Yin, Xiaoshan Zhao*, Qirui Wang*, Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2. Phytomedicine, 2023-06-01, 114:154764.  (IF=7.9)

10. Lun Liang#, Liangbao Wen#, Shixing Qin#, Zhenqiang He, Jie Lu, Run Cui, Xiaobing Jiang, Hongrong Hu, Sheng Zhong, Chang Li, Chengwei Yu, Yuang Xie, Zhenning Wang*, Hao Duan* (共同通讯作者), Yonggao Mou*, Poor Karnofsky performance status is not a contraindication for neurosurgical resection in patients with lung cancer brain metastases: a multicenter, retrospective PSM- IPTW cohort study. Journal of Neuro-oncology, 2023-03-20, 162, (2):327-335. (IF=3.9)

11. Jiahao Bao#; Weicheng Lu#; Hao Duan# (共一排第三); Yaqi Ye; Jiangbo Li; Wenting Liao; Yongchun Li; Yangpeng Sun: Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas, Front Immunol. 2022 Aug 15;13:933973. (IF=8.78)

12. Suwen Wu#; Chune Gan#; Xiaoling Huang#; Dongping Jiang; Ye Xu; Yixia Liao; Fen Ma; Yutong Hong; Hao Duan (通讯作者); Peng Lin: Incidence and risk factors of postoperative nausea and vomiting in lung cancer patients following lobectomy and application of analgesic pumps, J Int Med Res. 2022 Jun;50(6):3000605221105343. (IF=1.57)

13. Hao Duan# (共一排第一); Xiaobing Jiang#; Chang Li#; Mingyuan Chen; Bei Zhang; Yuanyuan Huang; Qingyu Zhao; Yonggao Mou: Application of a three-dimensional printed model to localize a cranial cerebrospinal fluid leak: a case report, J Int Med Res. 2022 Feb;50(2):3000605221078412. (IF=1.57)

14. Wanming Hu#; Hao Duan# (共一排第二); Sheng Zhong#; Jing Zeng; Yonggao Mou; High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?, Journal of Translational Medicine, 2022, 20(1): 0-64. (IF=8.44)

15. Fan Yang#; Zhenqiang He#; Hao Duan# (共一排第三); Duo Zhang; Juehui Li; Huijuan Yang; Jay F Dorsey; Wei Z ou; S Ali Nabavizadeh; Stephen J Bagley; Kalil Abdullah; Steven Brem; Lin Zhang; Xiaowei Xu; Kate lyn T Byrne; Robert H Vonderheide; Yanqing Gong; Yi Fan ; Synergistic immunotherapy of glioblasto ma by dual targeting of IL-6 and CD40, Nature Communications, 2021, 12. (IF=17.70)

16. Liling Liu#; Yuanzhong Yang#; Hao Duan# (共一排第三); Jiahua He; Lu Sun; Wanming Hu; Jing Zeng: CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas, Frontiers in Oncology. 2021 Apr 15;11:611038. (IF=5.74)

17. Luqiang Wang#; Lutian Yao#; Hao Duan# (共一排第三); Fan Yang; Maohuan Lin; Rongxin Zhang; Zhenqiang He; J aimo Ahn; Yi Fan; Ling Qin; Yanqing Gong ; Plasminogen Regulates Fracture Repair by Promoting the Functions of Periosteal Mesenchymal Progenitors, Journal of Bone and Mineral Research, 2021.11, 3 6(11): 2229-2242. (IF=6.39)

18. Hao Duan# (共一排第一); Zhenqiang He#; Maohuan Lin; Yanling Wang; Fan Yang; R. Alan Mitteer; Hyun-Jun Ki m; Eujing Yeo; Hongyu Han; Ling Qin; Yi Fan; Yanqing Gong; Plasminogen regulates mesenchymal ste m cell-mediated tissue repair after ischemia through Cyr61 activation, JCI INSIGHT, 2020, 5(15): 0-e131376. (IF=9.48)

19. Hao Duan# (共一排第一); Jilong Hu#; Zhenghe Chen; Juehui Li; Zhenqiang He; Zhenning Wang; Guanhua Zhang; Xiaoyu Guo; Lun Liang; Yonggao Mou; Assessment of circulating tumor DNA in cerebrospinal fluid by whole exome sequencing to detect genomic alterations of glioblastoma, Chinese Medical Journal, 2020;133(12). (IF=6.13)

20. Depei Li#; Hao Duan#(共一排第二); Pingping Jiang; Xiaobing Jiang; Zhenqiang He; Chengcheng Guo; Yonggao Mou: Trend and socioeconomic disparities in survival outcome of metastatic melanoma after approval of immune checkpoint inhibitors: a population-based study, Am J Transl Res. 2020 Jul 15;12(7):3767-3779. (IF=3.94)

六、获奖及荣誉

第六届广东医学科技奖一等奖

广州日报“2026实力医生”

更新时间：2026.9.18